Close Menu

NEW YORK – Oncocyte announced on Friday it has reached definitive agreements with institutional investors that will purchase about $10.7 million of the company's common shares in a registered offering.

The investors, which include Blackcrane Capital, will purchase the shares at an at-the-market price of $2.27 per share, the closing price of Oncocyte's stock immediately preceding the offering. Oncocyte is selling about 4.7 million shares in the offering, which is expected to close next week.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.